venous angiotensin II (ANG II) increases uterine vascular resistance (UVR), whereas uterine intra-arterial infusions do not. Type 2 ANG II (AT2) receptors predominate in uterine vascular smooth muscle; this may reflect involvement of systemic type 1 ANG II (AT1) receptormediated ␣-adrenergic activation. To examine this, we compared systemic pressor and UVR responses to intravenous phenylephrine and ANG II without and with systemic or uterine ␣-receptor blockade and in the absence or presence of AT1 receptor blockade in pregnant and nonpregnant ewes. Systemic ␣-receptor blockade inhibited phenylephrine-mediated increases in mean arterial pressure (MAP) and UVR, whereas uterine ␣-receptor blockade alone did not alter pressor responses and resulted in proportionate increases in UVR and MAP. Although neither systemic nor uterine ␣-receptor blockade affected ANG II-mediated pressor responses, UVR responses decreased Ͼ65% and also were proportionate to increases in MAP. Systemic AT1 receptor blockade inhibited all responses to intravenous ANG II. In contrast, uterine AT1 receptor blockade ϩ systemic ␣-receptor blockade resulted in persistent proportionate increases in MAP and UVR. Uterine AT2 receptor blockade had no effects. We have shown that ANG II-mediated pressor responses reflect activation of systemic vascular AT1 receptors, whereas increases in UVR reflect AT1 receptor-mediated release of an ␣-agonist and uterine autoregulatory responses. angiotensin receptors; autoregulation; pregnancy; uterine blood flow; blood pressure MAMMALIAN PREGNANCY IS ASSOCIATED with numerous cardiovascular changes (14, 28, 46, 49) , including attenuated pressor responses to systemic infusions of angiotensin II (ANG II) and catecholamines, suggesting decreased peripheral vascular sensitivity (1, 8, 22, 31, 42, 53) . As in the kidney (28), the uterine vascular bed also becomes refractory to these agents (18, 32, 42, 49, 52, 53) ; however, there is greater uterine sensitivity to ␣-agonists than to ANG II (10, 13, 31, 48, 49) . In contrast, systemic pressor responses to ANG II generally exceed those observed with ␣-agonists (42, 48, 49). These differences in systemic and uteroplacental vascular responsiveness to these vasoconstrictors are unclear, but they may be due to inherent mechanisms necessary for maintaining uterine blood flow (UBF) during pregnancy, when circulating levels of ANG II are normally increased. This theory is supported by reports that systemic (22, 58) and uteroplacental (17) refractoriness to ANG II and catecholamines is lost in women with pregnancyinduced hypertension, which may contribute to increases in fetal growth restriction and fetal/neonatal mortality and morbidity (15, 28, 46) . Thus it is important to understand the mechanisms that mediate uterine vascular refractoriness in normal mammalian pregnancy.
mechanisms that mediate uterine vascular refractoriness in normal mammalian pregnancy.
The uterine refractoriness to systemic ANG II infusions is not due to increases in ANG II clearance or decreases in ANG II (AT) receptor binding density in uterine vascular smooth muscle (VSM) (29, 40, 48) . However, as in the renal vasculature (21, 28) , basal synthesis of uterine artery endotheliumderived prostacyclin (PGI 2 ) and nitric oxide (NO) increases substantially in normal ovine pregnancy, and ANG II further augments their synthesis (30, 32) , providing local mechanisms whereby responses to infused ANG II or other agonists may be attenuated. Alternatively, differences in AT receptor expression in uterine and systemic VSM could contribute to the attenuated uterine responses to infused ANG II. In women and sheep, uterine VSM predominantly expresses AT 2 receptors, which do not mediate VSM contractions (3, 11, 13) but may be associated with VSM relaxation (27, 33, 59) . In contrast, AT 1 receptors predominate in systemic VSM and are responsible for VSM contraction and, probably, systemic pressor responses (3, 11) . If AT 2 receptors predominate in uterine VSM but do not mediate vasoconstriction, this could contribute to the differences in uterine and systemic responses to intravenous ANG II infusions. If this is the case, it is unclear how intravenous ANG II infusions increase uterine vascular resistance (UVR) in women and sheep.
Uterine vascular responses to intravenous ANG II infusions are well described (10, 18, 42, 48, 53) , whereas responses to uterine intra-arterial ANG II infusions are not as well studied (10, 12) . In a recent report, we (12) observed that intravenous ANG II dose dependently increased mean arterial pressure (MAP) and UVR and decreased UBF in the expected manner. In contrast, infusions via a uterine artery catheter had no pressor effect and did not alter UVR or UBF, suggesting that intravenous ANG II increases UVR via secondary mechanisms that could include increases in endothelin release (7) , sympathetic outflow (4, 45) , or adrenal catecholamine secretion (5, 44) . In the present studies, we determined whether systemic and uterine vascular responses to intravenous ANG II infusions are due to different mechanisms and whether this is altered in the final month of ovine pregnancy. We hypothesized that systemic pressor responses reflect peripheral VSM AT 1 receptor activation, whereas increases in UVR are due to ANG II-mediated release of ␣-agonists into the systemic circulation.
METHODS
Animal preparation. Twenty pregnant ewes Ն115 days gestation (full term ϭ 145 Ϯ 5 days) and 13 nonpregnant oophorectomized ewes of mixed Western breed were included in these studies. The chronically instrumented animal preparations used in these studies have been described in detail elsewhere (12, 42, 52) . Briefly, with the animals under inhalation anesthesia, electromagnetic flow probes (Carolina Medical, King, NC) were implanted on both main uterine arteries (6.0 -7.0 and 3.0 -3.5 mm ID for pregnant and nonpregnant animals, respectively). Polyvinyl catheters filled with heparinized saline (250 U/ml) were inserted retrograde 1-2.5 cm into a distal branch of the uterine artery supplying each uterine horn for local drug infusions and into the lower abdominal aorta (the tip lying at the trifurcation) and inferior vena cava (the tip lying just below the diaphragm) via a femoral artery and vein, respectively, to monitor arterial pressure and infuse drugs systemically, respectively. The ovaries of nonpregnant ewes were surgically removed. The flow probes and catheters were externalized to the flank through a subcutaneous tunnel and maintained in a canvas pouch attached to the skin with steel pins. The catheters were flushed daily with heparinized saline (250 U/ml) and closed with sterile pins. Intramuscular penicillin (600,000 U) and gentamicin (40 mg) were given on the day of surgery and on the following 2 postoperative days. Intravenous benamine was given for postoperative discomfort and pain. Each animal recovered for Ն5 days before the studies were initiated. Ovariectomized nonpregnant ewes received daily estrogen replacement with estradiol-17␤ (Sigma Chemical, St. Louis, MO; 1.0 g ⅐ kg Ϫ1 ⅐ day Ϫ1 ) beginning on postoperative days 4 -5, but not within 24 h of a study, as previously described (12, 31) . Castrated nonpregnant ewes were studied to control for cyclic changes in ovarian estrogen and/or progesterone synthesis, which are known to modify vascular sensitivity to ANG II and ␣-agonists (49) . These studies were approved by the Institutional Animal Care and Research Advisory Committee at the University of Texas Southwestern Medical Center.
Experimental protocols. Five protocols were designed to assess the mechanisms whereby intravenous ANG II infusions mediate systemic pressor and uterine vascular responses. When possible, animals were included in several protocols; however, malfunction of infusion catheters or flow probes often precluded achieving this goal. Pregnant animals were studied at several gestational ages in each protocol to determine whether changes in the maternal hormonal milieu and/or vasculature in the last month of pregnancy modified the pressor and/or uterine vascular responses to the agonists and/or antagonists used (49, 52) , precluding their inclusion in all protocols. All pregnant ewes delivered a live-born lamb at completion of these studies. Nonpregnant animals were studied once in each protocol. Baseline hemodynamic data were obtained in each protocol before infusion of a drug, and experimental values were obtained at 5-7 min of a constant infusion, when steady-state responses for MAP and UBF were established (13, 32, 48) .
In protocol 1, we characterized the systemic pressor and uterine vascular responses to the ␣1-agonist phenylephrine (PE) and the efficacy of systemic infusion of an ␣-receptor antagonist in inhibiting these responses. This permitted us to subsequently compare responses to infused ANG II. PE (Sigma Chemical) was diluted in sterile isotonic saline and infused through a femoral venous catheter with a constant-infusion pump (Harvard Apparatus, S. Natick, MA) at 0.75-1.5 g ⅐ min Ϫ1 ⅐ kg Ϫ1 for 7 min to establish steady-state responses. This dose decreases UBF ϳ30% in pregnant and nonpregnant ewes and is comparable to responses seen with systemic infusions of ANG II at 0.046 g ⅐ min Ϫ1 ⅐ kg Ϫ1 , which result in physiological blood levels of the peptide (38) . This was repeated in the presence of a continuous intravenous infusion of the ␣-receptor antagonist phentolamine (Phen; Sigma Chemical) at 180 g ⅐ min Ϫ1 ⅐ kg Ϫ1 , which was initiated 5 min before and continued throughout the PE infusion. This dose of Phen was observed in preliminary studies to inhibit PE-induced decreases in UBF in pregnant and nonpregnant ewes. Nine experiments were performed in four pregnant ewes between 132 and 144 days gestation and one each in seven nonpregnant sheep.
Protocol 2 was designed to determine whether ␣-receptor activation mediated systemic pressor and uterine vascular responses to intravenous ANG II infusions. ANG II (human; Sigma Chemical) was diluted in sterile isotonic saline to 3 g/ml and infused via a femoral venous catheter at 0.046 g ⅐ min Ϫ1 ⅐ kg Ϫ1 in the absence of systemic ␣-receptor blockade. As noted above, this dose of ANG II decreases UBF ϳ30% and results in physiological plasma levels of the peptide (38) ; therefore, responses are more likely to have physiological relevance. This procedure was repeated in the presence of systemic ␣-receptor blockade with Phen at 32-180 g ⅐ min Ϫ1 ⅐ kg Ϫ1 , permitting the establishment of dose-inhibition curves that included a Phen dose that abolished ANG II-induced decreases in UBF. Experiments were performed in eight pregnant ewes between 124 and 149 days gestation that were not included in protocol 1 and in the seven nonpregnant sheep included in protocol 1. Studies were initiated in the latter 30 min after completion of protocol 1, allowing for the clearance of ␣-receptor blockade and for return of hemodynamic parameters to baseline. In preliminary studies, we observed that responses to PE at that time were similar to those seen before ␣-receptor blockade with Phen.
Protocol 3 was designed to determine the effects of local uterine artery infusions of the vascular ␣-receptor antagonist Phen on systemic pressor and uterine vascular responses to intravenous PE and ANG II infusions in pregnant ewes. PE was infused through a femoral venous catheter at 0.75-1.5 g ⅐ min Ϫ1 ⅐ kg Ϫ1 for 7 min in the absence or presence of a continuous infusion of Phen via a uterine artery catheter calculated to achieve an arterial concentration of ϳ10 ng/ml, which in preliminary studies abolished PE-induced decreases in UBF. The rate of infusion in nanograms per minute was calculated for each experiment from the desired arterial concentration (ng/ml) ϫ UBF (ml/min), which was continuously measured with flow probes (12) . The study was repeated using intravenous ANG II (0.046 g ⅐ min Ϫ1 ⅐ kg Ϫ1 ) in the absence and then presence of uterine ␣-receptor blockade with Phen. All but one of the animals included in these studies were studied in protocol 1. Five received PE ϩ local Phen between 132 and 144 days gestation, and three received ANG II ϩ local Phen between 120 and 142 days gestation.
During the course of these studies, increases in UVR during systemic ANG II infusions were not completely blocked by systemic (protocol 2) or uterine (protocol 3) ␣-receptor blockade. Because AT 1 receptors account for 15-20% of uterine VSM AT receptor binding (11, 13) , their activation might account for the residual effects of ANG II on UVR. Therefore, we examined the vascular responses to intravenous infusions of ANG II ϩ Phen in the absence and presence of uterine AT1 receptor blockade in pregnant and nonpregnant ewes (protocol 4). L-158809, a specific AT 1 receptor antagonist (kindly provided by Merck Pharmaceuticals, Rahway, NJ), was reconstituted in isotonic saline (1 mg/ml) and infused over 1 min via a uterine artery catheter in 0.1-mg incremental bolus doses while MAP, heart rate, and UBF were continuously monitored. At 5 min after completion of each infusion, systemic ␣-receptor blockade was induced with Phen (180 g ⅐ min Ϫ1 ⅐ kg Ϫ1 ) followed by the intravenous infusion of ANG II (0.046 g ⅐ min Ϫ1 ⅐ kg Ϫ1 ). This sequence was repeated until the rise in MAP decreased from that observed with intravenous ANG II alone. At this point, L-158809 was considered to have saturated uterine VSM AT1 receptors and "spilled over" into the systemic circulation, blocking systemic VSM AT1 receptors and altering pressor responses, an approach previously used in studies of ANG II (12) . The total cumulative intra-arterial dose of L-158809 was 0.3-0.6 mg in pregnant and nonpregnant ewes. Studies were performed in three pregnant ewes between 134 and 146 days gestation and four nonpregnant animals. Because of the ever-present question of the role of the AT2 receptor in modulating UBF and vascular responses (27, 33) , the effect of uterine VSM AT2 receptor blockade was similarly studied using the AT2 receptor antagonist PD-123319 (kindly provided by Parke-Davis Pharmaceutical, Ann Arbor, MI). Cumulative intra-arterial bolus doses were 0.3-12.0 and 0.15-0.3 mg in pregnant and nonpregnant animals, respectively. The dose range was expanded in the former because of high basal UBF. Studies were performed in three pregnant sheep between 133 and 145 days gestation and in four nonpregnant ewes.
Having demonstrated in protocols 1-4 that ANG II mediates 65-70% of the rise in UVR through a secondary mechanism involving an ␣-agonist that does not facilitate the pressor response (see RESULTS) and knowing that adrenal catecholamine secretion occurs via an AT 1 receptor-mediated mechanism (57), we examined the effects of systemic AT 1 receptor inhibition on ANG II-mediated systemic pressor responses and increases in UVR (protocol 5). Systemic and uterine responses to ANG II (0.046 g ⅐ min Ϫ1 ⅐ kg Ϫ1 ) were determined in the absence and presence of systemic AT1 receptor blockade with L-158809, which was infused intravenously (0.5 mg) over 1 min in three pregnant ewes studied between 130 and 145 days gestation.
Hemodynamic measurements. During all studies, MAP, heart rate, and UBF were continuously monitored with a six-channel pen recorder (Gould, Cleveland, OH), and data were recorded using the PONEMAH data acquisition system (PNM-P3-P-010, Gould, Valley View, OH). MAP and heart rate were monitored through a femoral artery catheter attached to a pressure transducer (type 4-327-0109, Bell and Howell, Pasadena, CA) connected to an amplifier (model N-4307-04, Gould); heart rate was obtained from the integrated phasic signal. UBF was monitored with electromagnetic flowmeters (model 501, Carolina Medical) with linear responses to flows in the range studied and a flow signal and zero-flow calibration. Flow probes are routinely calibrated in vitro and have a measurement error of 5-10%. Baseline UBF in nonpregnant ewes is 15-30 ml/min in each uterine horn; thus the sensitivity of the recording system was increased to quantify the changes in UBF in nonpregnant sheep as previously reported (12, 31) . UVR (mmHg ⅐ min ⅐ l Ϫ1 ) was calculated as MAP (mmHg) Ϭ UBF (ml/min). No animal was studied on consecutive days. Measurements of UBF and UVR reflect the uterine horn being studied, because in several animals there was a nonfunctional flow probe during the course of these studies.
Statistical methods. Experimental observations derived from multiple experiments in a ewe were averaged, resulting in an n value that reflects averaged data from a single animal. Because basal measurements of hemodynamic variables differ in pregnant and nonpregnant ewes (Table 1) and have different units of measurement and we wished to compare responses between groups and variables, we examined the relative changes in each variable, i.e., the percent change from baseline, which takes these differences into account (12, 42) . Student's t-test was used to determine changes from baseline, with Welch's approximation applied where applicable. Repeatedmeasures ANOVA was used to examine changes across doses. Twoway ANOVA and all pairwise multiple comparison procedures (Tukey's test) were used to determine differences between responses to systemic and local ANG II infusions. Linear regression analysis with the least squares method was employed to determine whether there were differences in responses to agonists and/or antagonists across gestational ages. Values are means Ϯ SE.
RESULTS
Baseline hemodynamic data. Cardiovascular measurements were obtained from 9 pregnant ewes between 124 and 149 days gestation and 11 nonpregnant ewes before infusion of PE, ANG II, or Phen to examine the differences in basal hemodynamics. As expected (47) , basal heart rate and UBF were greater (Table 1) and UVR was decreased 95% (P Ͻ 0.001) in pregnant animals. MAP was lower, but this was not statistically significant. There were no detectable changes in these variables in the last 3 wk of pregnancy (P Ͼ 0.2 by regression analysis), likely reflecting the relatively short period of pregnancy studied. Because significant differences exist in basal hemodynamic values in pregnant and nonpregnant animals, comparisons should be made using the relative changes (12, 42) .
Next, we analyzed data collected before and after systemic and/or local uterine vascular ␣-blockade with Phen to examine the effects of ␣-adrenergic blockade on basal hemodynamics (Table 2) . Basal MAP, UBF, and UVR were unaffected by systemic Phen infusions of 32-180 g⅐min Ϫ1 ⅐kg Ϫ1 in pregnant and nonpregnant ewes (P Ն 0.1). There was, however, a modest rise in heart rate in both groups (Table 2) . Uterine artery infusions of Phen calculated to achieve a concentration of ϳ10 ng/ml also had no effect on basal UBF or UVR in pregnant ewes and did not affect MAP (P Ն 0.8; Table 2 ).
Effects of systemic ␣-receptor blockade on responses to intravenous PE and ANG II. The effects of systemic ␣-blockade on responses to intravenous PE were examined in four pregnant ewes between 124 and 149 days gestation and seven nonpregnant sheep (protocol 1). In this and subsequent studies, there was no significant effect of gestational age (P Ͼ 0.1 by regression analysis) on the responses by any hemodynamic variable to ␣-receptor stimulation, ANG II, or ␣-receptor inhibition in the last 3 wk of gestation; thus studies performed at different gestational ages were averaged to provide a single value for each pregnant animal included in the analysis. Intravenous PE (0.75-1.5 g⅐min Ϫ1 ⅐kg Ϫ1 ) consistently increased (P Ͻ 0.05) MAP and UVR and decreased (P Ͻ 0.05) UBF in the pregnant animals (Fig. 1A) . However, the rise in UVR was nearly threefold greater than the rise in MAP. These responses Values are means Ϯ SE from 9 pregnant ewes (124 -149 days) obtained from protocol 1 and 11 nonpregnant ewes obtained from protocols 1 and 2. MAP, mean arterial pressure; HR, heart rate; UVR, uterine vascular resistance; UBF, uterine blood flow. Measurements of UBF represent the study artery in 1 uterine horn. *Significantly different from nonpregnant (P Ͻ 0.001 by nonpaired t-test). ) and local (10 ng/ml) phentolamine. Measurements of UBF represent the study artery in 1 uterine horn. *Significantly different from basal (P ϭ 0.005 by Tukey's test).
were abolished during continuous intravenous infusions of Phen (180 g⅐min Ϫ1 ⅐kg Ϫ1 ). Nonpregnant ewes responded similarly (Fig. 1B); i.e., intravenous PE (1.0 g⅐min Ϫ1 ⅐kg Ϫ1 ) increased (P Ͻ 0.05) MAP and UVR while decreasing (P Ͻ 0.05) UBF, and the rise in UVR was more than threefold greater than the rise in MAP. As in the pregnant group, systemic ␣-receptor blockade with Phen abolished (P Ͻ 0.005) all the hemodynamic responses to PE (Fig. 1B) .
To determine whether the vascular responses to systemic ANG II infusions involve ␣-receptor activation, intravenous ANG II was infused before and after systemic ␣-receptor blockade with Phen (protocol 2) in eight pregnant ewes between 124 and 149 days gestation. As noted earlier, there was no effect of gestational age on the responses. Systemic ANG II (0.046 g ⅐min Ϫ1 ⅐kg
Ϫ1
) alone increased (P Ͻ 0.005) MAP 35 Ϯ 3% ( Fig. 2A) and UVR 79 Ϯ 7.7% (Fig. 2B ) while decreasing (P Ͻ 0.001) UBF 22 Ϯ 2% (Fig. 2C) . Systemic ␣-receptor blockade with Phen dose dependently inhibited the ANG II-mediated rise in UVR ( Fig. 2B ; P ϭ 0.006 by ANOVA) and fall in UBF ( Fig. 2C ; P Ͻ 0.001 by ANOVA) but did not affect the rise in MAP ( Fig. 2A ; P ϭ 0.5 by ANOVA). Although the highest dose of Phen completely inhibited (P ϭ 0.1 by paired t-test) the fall in UBF, UVR rose Ͼ32%, demonstrating a residual effect of ANG II on UVR that was proportionate to the rise in MAP.
A similar pattern of responses was observed in nonpregnant ewes (n ϭ 6; Fig. 3 ). In the absence of ␣-receptor blockade, intravenous ANG II (0.046 g⅐ min Ϫ1 ⅐kg Ϫ1 ) increased MAP ( Fig. 3A ; P Ͻ 0.001) and UVR ( Fig. 3B ; P Ͻ 0.001) and decreased UBF ( Fig. 3C ; P Ͻ 0.04); however, the rise in MAP and UVR was twofold greater (P Ͻ 0.04) than in the pregnant animals. As in the pregnant group, systemic ␣-receptor blockade had no significant effect on the ANG II-induced rise in MAP (P ϭ 0.4 by ANOVA; Fig. 3A ), but the rise in UVR ( Fig.  3B ; P Ͻ 0.001 by ANOVA) and fall in UBF ( Fig. 3C ; P Ͻ 0.04 by ANOVA) were inhibited dose dependently. Although the highest dose of Phen abolished the fall in UBF, there again was a ϳ40% rise in UVR that was parallel to and proportionate with the rise in MAP.
Effects of uterine vascular ␣-receptor blockade on responses to intravenous PE and ANG II.
Having demonstrated that systemic ␣-receptor blockade abolished all the responses to intravenous PE but only inhibited the changes in UVR and UBF during intravenous ANG II, we examined the effects of local uterine artery ␣-receptor blockade on responses to intravenous PE and ANG II in three pregnant ewes studied between 132 and 144 days gestation (protocol 3). PE was infused in the absence and presence of uterine artery infusions of Phen. There were no gestational effects on the responses to PE or uterine ␣-receptor blockade. Uterine ␣-receptor blockade with Phen inhibited PE-induced increases in UVR 72% (P ϭ 0.009) and decreases in UBF Ͼ82% (P Ͻ 0.001) but did not alter the 25-30% rise in MAP, demonstrating selective uterine vascular ␣-adrenergic blockade and maintenance of the systemic pres- sor response. The rise in MAP was paralleled by a proportionate rise in UVR.
To further delineate the contribution of ␣-adrenergic activation in the effects of intravenous ANG II on UVR and UBF and remove the effects of systemic ␣-receptor blockade, Phen was directly infused into the uterine vascular bed of one uterine horn (protocol 3) to achieve and maintain an arterial concentration of ϳ10 ng/ml, which, as noted above, inhibited the uterine responses to PE Ͼ70%. A representative experiment is illustrated in Fig. 4 , where the effects of systemic ANG II alone (Fig. 4A ) and the effects of systemic ANG II ϩ Phen infused into the left uterine horn (Fig. 4B) are shown. The right uterine horn, which served as an internal control, demonstrates an intact response to intravenous ANG II; i.e., UBF falls soon after initiation of the ANG II infusion in the absence and presence of the contralateral arterial infusion of Phen. In contrast, the infused uterine horn demonstrates a markedly attenuated UBF response. Although the ANG II-mediated rise in MAP was unaffected by uterine ␣-receptor blockade ( Fig. 5 ; P ϭ 0.9), the rise in UVR was inhibited Ͼ63% (P Ͻ 0.001) and the fall in UBF Ͼ90%. Thus local uterine vascular ␣-receptor blockade resulted in a proportionate rise in MAP and UVR (Fig. 5) .
Effect of systemic ␣-receptor blockade ϩ local uterine vascular AT 1 receptor blockade on responses to intravenous ANG II. Although systemic infusions of Phen in pregnant and nonpregnant ewes and local uterine artery infusions in pregnant ewes decreased the rise in UVR during intravenous ANG II infusions, we observed a persistent 25-35% increase in UVR (Figs. 2B, 3B, and 5 ). This suggests that another mechanism is involved in the ANG II-mediated increases in UVR. Because AT 1 receptors account for ϳ15% of AT receptor binding in uterine VSM (11, 13) , this might explain the residual rise in UVR. Thus we incrementally blocked AT 1 receptors in the uterine vascular bed of one horn with cumulative intra-arterial doses of L-158809 (protocol 4). Studies were performed in three pregnant ewes between 134 and 146 days gestation and four nonpregnant ewes. Systemic infusions of Phen ϩ uterine AT 1 receptor blockade did not alter the ANG II-mediated rise in UVR in pregnant or nonpregnant sheep, which was proportional to the rise in MAP (Fig. 6 ) and resembled the responses seen with local uterine artery ␣-receptor blockade in the presence of intravenous ANG II ( Fig. 5; protocol 3 ). The fall in UBF was completely inhibited. The residual rise in UVR tended to be greater in nonpregnant animals: 53 Ϯ 15% vs. 33 Ϯ 4.6% (P ϭ 0.3). AT 2 receptors predominate in uterine VSM and may attenuate UVR responses to infused ANG II (11, 13, 27, 33) . To determine whether AT 2 receptor activation played a role, we infused cumulative intra-arterial doses of the AT 2 Although ␣-receptor blockade modified uterine responses to systemic ANG II infusions, the mechanism for ANG II-mediated release of ␣-receptor agonist was unclear. This appears to occur via an AT 1 receptor-mediated event (57) . Therefore, we examined the effects of systemic AT 1 , and 26 Ϯ 5.1 vs. 24 Ϯ 4.6 ml/min, respectively), but there was complete inhibition (P Ͻ 0.01) of ANG II-mediated increases in MAP and UVR and decreases in UBF (Fig. 7B) . .005 by paired t-test) . †Significantly different from absence of systemic AT1 blockade (P Յ 0.01 by paired t-test).
DISCUSSION
The uterine and systemic vasculature of pregnant women and sheep are refractory to ANG II and ␣-receptor agonists (11, 18, 31, 42, 48, 53) , but the responses to these agents differ in these vascular beds (10, 32, 42, 48) . Hypertensive pregnant women lose this refractoriness (17) , demonstrating increases in UVR and fetal morbidity (14, 15, 28, 46) . Thus understanding the molecular, cellular, and physiological mechanisms responsible for these vascular changes in normotensive and hypertensive pregnancies is medically important. We report novel observations demonstrating that 1) the differences in the uterine and systemic responses to ANG II and ␣-receptor agonists are inherent to these vascular beds and unchanged by pregnancy, 2) the effects of ANG II on uterine and systemic vasculature occur through entirely different mechanisms, and 3) the uterine vascular bed in pregnancy is sensitive to increases in perfusion pressure, suggesting that local autoregulatory mechanisms contribute to the regulation of UBF. These findings not only extend our understanding of uterine vascular changes in pregnancy but also provide new insights into the mechanisms whereby maternal hypertension may alter fetal growth and well-being through changes in UVR.
The ovine uteroplacental vascular bed, similar to the kidney (28) , is refractory to the vasoconstricting effects of intravenous physiological doses of ANG II during normotensive pregnancy (12, 38, 48, 49, 53) . Furthermore, the ANG II-mediated increases in UVR are generally less than simultaneous rises in systemic vascular resistance (SVR) and MAP; therefore, increases in perfusion pressure contribute to the maintenance of UBF (42, 48) . In contrast, intravenous physiological doses of ␣-receptor agonists increase UVR in the absence of simultaneous changes in SVR or MAP, and UBF falls (31, 49, 54) . In the present study, the pattern of the responses to systemic ANG II and PE were strikingly similar in pregnant and nonestrogenized nonpregnant sheep, confirming our (12) recent suggestion that mechanisms inherent within the uterine and systemic vascular beds account for these differences. In pregnancy, the attenuated uterine responses to ANG II could be explained by the lack of responsiveness by the placental vasculature (53) , which accounts for Ն80% of total UBF at full term (49) , or the increased synthesis of local vasodilators (30, 32) . However, both are specific to pregnancy and, therefore, do not explain the similarity in uterine responses in pregnant and nonpregnant ewes. In contrast, responses to ␣-receptor agonists by the placental and myoendometrial vasculature in intact animals (31, 49, 54) and uterine arteries in vitro (2, 23, 43) exceed the response in the systemic vasculature. Although this may reflect a predominance of ␣ 1 -receptors in uterine vs. systemic arteries (20, 25) , this remains controversial and requires further study. Physiologically, the insensitivity of the uterine vasculature to ANG II would protect it from elevated plasma levels normally seen in pregnancy as well as further increases after orthostatic changes. On the other hand, the greater sensitivity to ␣-receptor agonists permits the rapid redistribution of 20 -25% of cardiac output from the gravid uterus to essential organs and tissues, thereby ensuring maternal well-being during stresses. In the absence of such stresses, the overall uterine refractoriness associated with pregnancy provides a large margin of safety for the fetus (49).
The differences in uterine and systemic vascular responses to intravenous ANG II are unlikely to be due to the additive effects of increases in basal uterine artery endothelial synthesis of NO-and PGI 2 ϩ ANG II-mediated increases, because both are specific to pregnancy (30, 32, 48) . In addition, AT receptor binding density is similar in ovine uterine and mesenteric VSM, and neither changes in pregnancy (29) , excluding this as well. However, AT 2 receptors, which do not mediate ANG II-induced contractions (3), account for Ͼ80% of binding in uterine VSM from women and sheep and are unchanged in pregnancy, whereas AT 1 receptors predominate in peripheral VSM (11, 13) . This difference in AT receptor subtype expression could explain the similar differences in uterine and systemic responses to ANG II in pregnant and nonpregnant ewes but does not explain how intravenous ANG II increases UVR. One possibility is that intravenous ANG II increases the synthesis or release of another vasoconstrictor. This is supported by recent observations that intra-arterial infusions of physiological doses of ANG II do not alter UVR or UBF in pregnant and nonpregnant sheep (12) . ANG II is known to elicit ␣-receptor-mediated responses and adrenal catecholamine release (5, 44, 45, 57) . In the present study, uterine and systemic ␣-receptor blockade caused a 70 -75% reduction in the rise in UVR during systemic ANG II infusions, suggesting that ANG II increases adrenal catecholamine secretion (5, 44, 45) . Although plasma catecholamines were not measured, inhibition of uterine responses to ANG II after uterine and systemic ␣-receptor blockade is convincing. Furthermore, complete inhibition of these responses occurred after systemic AT 1 blockade, consistent with AT 1 receptor-mediated secretion of adrenal catecholamines (57) . In contrast, systemic ␣-receptor blockade did not modify ANG II-induced increases in MAP, demonstrating that ␣-receptor stimulation does not contribute to the systemic pressor responses, whereas the converse occurs in the uterine vasculature (31, 49) . This is the first report demonstrating that uterine and systemic responses to intravenous ANG II occur via AT 1 receptor activation, but through different mechanisms, the former predominantly via the release of an ␣-receptor agonist, very likely of adrenal medullary origin (5, 44, 57) . Surprisingly, there were persistent increases in UVR during intravenous ANG II after ␣-receptor blockade that were greater in nonpregnant ewes. AT 1 receptors account for ϳ15% of binding in uterine VSM and could mediate this residual rise in UVR (11, 13) . However, uterine AT 1 receptor blockade did not affect responses in either group of sheep, suggesting that VSM AT 1 receptors do not contribute to ANG II-induced rises in UVR or that local vasodilators effectively inhibit their effects (30, 32) . ANG II-mediated increases in local PGI 2 require AT 1 receptor activation (11) ; thus this is an unlikely explanation. It does not exclude local NO synthesis, which, as in the kidney (21, 28) , increases in pregnancy (32) and could attenuate responses to ANG II. AT 2 receptor blockade also had no effect. Notably, the residual rise in UVR was consistently proportionate to the rise in MAP or perfusion pressure and also was observed during systemic PE infusions in the presence of uterine ␣-receptor blockade. Thus a sensitive autoregulatory mechanism appears to exist in the uterine vascular bed (34, 56) and is attenuated in normotensive pregnancy. Furthermore, it appears to contribute to the rise in UVR seen with intravenous PE and ANG II. Myogenic responses occur in the renal and mesenteric artery and are attenuated in pregnancy (21, 28, 35, 56) . They also have been observed in the uterine vasculature (9, 37, 43, 60) . Thus autoregulation, possibly via local myogenic mechanisms, appears to contribute to uterine responses to ANG II and ␣-receptor agonists. If uterine vascular refractoriness is absent in hypertensive pregnant women (58) , this may contribute to increases in UVR (17, 26, 56) , VSM remodeling, decreases in UBF, and, subsequently, fetal growth restriction.
SVR and UVR fall in pregnancy, but it is unclear how vascular tone is maintained. Increases in cardiac output occur early in pregnancy and facilitate the maintenance of MAP (14, 47, 49) . Sympathetic nervous activity and the renin-angiotensin system are normally upregulated (15, 24, 28) and may contribute to peripheral vascular tone. However, neither systemic ␣-adrenergic nor AT 1 receptor blockade alone altered basal MAP in the last 3 wk of ovine pregnancy. In estrogenized nonpregnant ewes, vascular tone also is maintained after isolated receptor blockade, whereas simultaneous ␣-receptor and AT receptor inhibition cause dramatic falls in MAP (16) . Therefore, both systems contribute to vascular tone after estrogen-induced vasodilation. In the present study, we have not excluded increases in sympathetic outflow, but existing data suggest that increases in cardiac output are primarily responsible for maintaining MAP in pregnancy (47) . Uterine ␣-adrenergic and AT 1 /AT 2 receptor blockade also had no effect on basal UVR or UBF in nonpregnant or pregnant ewes; the former is consistent with earlier observations (41) . These factors, therefore, do not independently contribute to basal systemic or uterine vascular tone in nonpregnant or pregnant ewes. Acute NO synthase and cyclooxygenase inhibition also minimally alter basal UVR and UBF (36, 39, 51) . However, inhibition of the large-conductance calcium-dependent potassium (BK Ca ) channel in the uterine vasculature decreases UBF in pregnant ewes (50) , but it is unclear to what extent the BK Ca channel modulates basal UVR and UBF in pregnancy.
We have demonstrated for the first time that intravenous ANG II increases UVR primarily through release of an ␣-receptor agonist, most likely adrenal catecholamines (4, 44, 57) , in nonpregnant and pregnant sheep and that local autoregulatory mechanisms contribute. In contrast, the resulting rise in circulating ␣-receptor agonists does not contribute to ANG II-mediated pressor responses, again demonstrating the enhanced sensitivity of the uterine vascular bed to ␣-receptor agonists, which we now report is an inherent property of this vascular bed. We now believe that ANG II-mediated increases in uterine artery endothelial PGI 2 and NO synthesis in pregnancy modify uterine autoregulation and responses to ␣-receptor agonists similar to that seen in the kidney (21) . If pregnancy-induced hypertension is associated with increased sympathetic outflow or ␣-adrenergic receptor activity and the loss of vascular refractoriness (17, 22, 24, 55) , prolonged increases in MAP may modify VSM remodeling, further increase UVR (26, 56) , decrease UBF, and increase the risk for abnormalities of uteroplacental oxygen delivery and, thus, fetal growth restriction (46, 49) . It may now be possible to develop strategies to address this problem.
